Who we are?

We are committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Our Pipeline

We focus on the discovery and development of innovative medicines to address significant unmet medical needs of diseases that are specially prevalent in Chinese population.

Dedicated and Deliver

We have built a fully integrated biopharmaceutical platform that allows us to oversee all aspects of the drug development cycle. By having all functions in-house, we are able to improve operational efficiency and control quality every step of the way.

Company News

Clinical Study Result of Orelabrutinib in Patients with R/R MCL Published by Blood Advances


InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL


Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting

This website uses cookies and similar technologies, to enhance your browsing experience and provide personalized recommendations. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our PRIVACY POLICY